Citadel Initiates Human Genome Sciences With Add Rating, $25 PT

August 8, 2011 6:02 AM | 7 seconds read |
Citadel Securities has initiated coverage on Human Genome Sciences HGSI with an Add rating and $25 price target.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Price TargetInitiationAnalyst RatingsBiotechnologycitadel securitiesHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!